Cite
MLA Citation
D.W. Rasco et al.. “300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma.” European journal of cancer, vol. 51, no. 3, n.d., pp. S53–S54. http://access.bl.uk/ark:/81055/vdc_100051431864.0x00002b